Mohan Timilsina

Mohan Timilsina

Auto-generated profile, based on publicly available information

Mohan Timilsina

Data Science Institute, Insight Centre for Data Analytics, University of Galway, Ireland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
MTMeera Tandan
Meera Tandan
Yogesh AcharyaYogesh Acharya
Yogesh Acharya
SPSuresh Pokharel
Suresh Pokharel
MTMohan Timilsina
Mohan Timilsina

24 June 2024 in Machine Learning with Applications
Verified
Journal Article
Open access
SPSumana Sharma Poudel
Sumana Sharma Poudel
SPSuresh Pokharel
Suresh Pokharel
MTMohan Timilsina
Mohan Timilsina

1 June 2021 in Applied Soft Computing
Verified
Journal Article
Open access
MTMohan Timilsina
Mohan Timilsina
AFAlejandro Figueroa
Alejandro Figueroa
MDMathieu D’aQuin
Mathieu D’aQuin
HYHaixuan Yang
Haixuan Yang

18 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MTMohan Timilsina
Mohan Timilsina
MTMeera Tandan
Meera Tandan
MDMathieu D’aquin
Mathieu D’aquin
HYHaixuan Yang
Haixuan Yang
Identifying the unintended effects of drugs (side effects) is a very important issue in pharmacological studies. The laboratory verification of associations between drugs and side effects requires costly, time-intensive research. Thus, an approach to predicting drug side effects based on known side effects, using a computational model, is highly desirable. To provide such a model, we used openly available data resources to model drugs and side effects as a bipartite graph. The drug-drug network is constructed using the word2vec model where the edges between drugs represent the semantic similarity between them. We integrated the bipartite graph and the semantic similarity graph using a matrix factorization method and a diffusion based model. Our results show the effectiveness of this integration by computing weighted (i.e., ranked) predictions of initially unknown links between side effects and drugs.

1 July 2023 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
AJAdrianna Janik
Adrianna Janik
MTMaria Torrente
Maria Torrente
LCLuca Costabello
Luca Costabello
VCVirginia Calvo
Virginia Calvo
BWBrian Walsh
Brian Walsh
Mariano ProvencioMariano Provencio
Mariano Provencio
PURPOSE: Stratifying patients with cancer according to risk of relapse can personalize their care. In this work, we provide an answer to the following research question: How to use machine learning to estimate probability of relapse in patients with early-stage non–small-cell lung cancer (NSCLC)? MATERIALS AND METHODS: For predicting relapse in 1,387 patients with early-stage (I-II) NSCLC from the Spanish Lung Cancer Group data (average age 65.7 years, female 24.8%, male 75.2%), we train tabular and graph machine learning models. We generate automatic explanations for the predictions of such models. For models trained on tabular data, we adopt SHapley Additive exPlanations local explanations to gauge how each patient feature contributes to the predicted outcome. We explain graph machine learning predictions with an example-based method that highlights influential past patients. RESULTS: Machine learning models trained on tabular data exhibit a 76% accuracy for the random forest model at predicting relapse evaluated with a 10-fold cross-validation (the model was trained 10 times with different independent sets of patients in test, train, and validation sets, and the reported metrics are averaged over these 10 test sets). Graph machine learning reaches 68% accuracy over a held-out test set of 200 patients, calibrated on a held-out set of 100 patients. CONCLUSION: Our results show that machine learning models trained on tabular and graph data can enable objective, personalized, and reproducible prediction of relapse and, therefore, disease outcome in patients with early-stage NSCLC. With further prospective and multisite validation, and additional radiological and molecular data, this prognostic model could potentially serve as a predictive decision support tool for deciding the use of adjuvant treatments in early-stage lung cancer.

12 March 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
MTMohan Timilsina
Mohan Timilsina
SBSamuele Buosi
Samuele Buosi
MRMuhammad Asif Razzaq
Muhammad Asif Razzaq
RHRafiqul Haque
Rafiqul Haque
CJConor Judge
Conor Judge
ECEdward Curry
Edward Curry
The lightning development of artificial intelligence (AI) has revolutionized healthcare, helping significant improvements in various applications. This paper provides a comprehensive review of foundation models in healthcare, highlighting their transformative potential in areas such as diagnostics, personalized treatment, and operational efficiency. We argue the key capabilities of these models, including their ability to process diverse data types such as medical images, clinical notes, and structured health records. Regardless their assurance, difficulties remain, including data privacy concerns, bias in AI algorithms, and the need for extensive computational resources. Our analysis identifies emerging trends and future directions, emphasizing the importance of ethical AI deployment, improved interoperability over healthcare systems, and the development of more robust, domain-specific models. Future research should focus on enhancing model interpretability, ensuring equitable access, and fostering collaboration between AI developers and healthcare professionals to maximize the advantages of these technologies.